Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 827 of 6351
-
Spinal zaps may steady blood pressure in spinal cord injury
Symptom relief OngoingThe goal of this interventional crossover study is to determine the effects of transcutaneous spinal cord stimulation (TSCS) on the ability to perform moderate exercise and regulate core body temperature in the chronic spinal cord injury community. The main questions it aims to a…
Sponsor: James J. Peters Veterans Affairs Medical Center • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
New drug combo aims to tackle Chemotherapy-Resistant colorectal cancer in the abdomen
Disease control OngoingThis is a two-center open-label non-randomized proof of principle study consisting of a dose-finding part (phase I) and phase II study with Simon two-stage design investigating the anti-tumor activity of the combination of capecitabine and galunisertib in patients with colorectal…
Phase 1/2 • Sponsor: The Netherlands Cancer Institute • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New RSV vaccine shows promise for transplant patients
Vaccine CompletedThe purpose of this study is to evaluate the immunogenicity, safety, and reactogenicity of the RSVPreF3 OA investigational vaccine in an immunocompromised (lung and renal transplant recipients) population and assess whether a second dose of the vaccine increases the immune respon…
Phase 2 • Sponsor: GlaxoSmithKline • Aim: Vaccine
Last updated Jun 27, 2026 13:05 UTC
-
Could a new drug match the standard for liver cancer treatment?
Disease control CompletedLittle is known about whether the types of chemotherapeutic agents affect the efficacy of transarterial chemoembolization in patients with hepatocellular carcinoma. Although doxorubicin is the most commonly-used chemotherapeutic agent in the world, idarubicin is recently in the s…
Phase 2 • Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Patch aims to cut rotator cuff Re-Tear rate after surgery
Disease control Recruiting nowRotator cuff (RC) injuries are particularly prevalent, difficult to repair, and attachment between the bone and tendon is notoriously difficult to achieve. The most common method and current standard of care (SOC) for reattaching connective tissues (e.g., ligaments, tendons) to b…
Phase 4 • Sponsor: Brooke Army Medical Center • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New drug cocktail aims to shrink Hard-to-Treat GI tumors
Disease control Recruiting nowThis study is to evaluate the efficacy of the LM-302 Combination With Other Therapies in patients with CLDN18.2-positive Advanced Digestive Tract Tumor.
Phase 2 • Sponsor: LaNova Medicines Zhejiang Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 16:47 UTC
-
Promising drug targets rare childhood cancers in new trial
Disease control Recruiting nowThe purpose of this study is to find out if a drug called lurbinectedin (the "study drug") is safe and effective at treating people with recurrent or relapsed solid tumors, including Ewing sarcoma.
Phase 1/2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New shot shows promise against fatty liver disease
Disease control CompletedPurpose of this study is to assess the effects of pemvidutide on NASH resolution and NASH fibrosis.
Phase 2 • Sponsor: Altimmune, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New combo therapy aims to knock out high-risk prostate cancer
Disease control Recruiting nowThis trial will evaluate whether the immune-sensitizing effects of immunotherapy (Pembrolizumab) and radiation with or without a PARP-inhibitor (Olaparib) will increase the effects of immunotherapy in men with high-risk localized prostate cancer.
Phase 2 • Sponsor: Zin W Myint • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Could two HPV shots be enough for women with HIV?
Vaccine Recruiting nowThere are very little data on human papillomavirus (HPV) vaccination among the 18 million women living with HIV (WLWH) globally, who constitute a population most vulnerable to HPV and the resultant cervical cancer. Particularly, there are no data to date on reduced-dose schedules…
Phase 4 • Sponsor: University of British Columbia • Aim: Vaccine
Last updated Jun 27, 2026 09:02 UTC
-
New RSV shot shows promise for vulnerable babies
Disease control CompletedThe purpose of this study is to measure the safety, PK, occurrence of ADA to nirsevimab, and anti-RSV neutralizing Ab in Japanese children with certain health conditions or pre-term infants aged ≤12 months. Study details include * The study duration is approximately 21 months w…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Can a Low-Sodium sleep drug ease daytime sleepiness in two sleep disorders?
Disease control CompletedThis study will assess the safety and efficacy of JZP258 (XYWAV) on sleepiness, polysomnography, and functional outcomes in patients with idiopathic hypersomnia (IH) or narcolepsy.
Phase 4 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can Lab-Grown tumor tissue reveal the best drug for each patient?
Knowledge-focused Recruiting nowThis biospecimen collection study will evaluate the feasibility of engrafting and testing resected Central nervous system (CNS) tumors tumor tissue ex vivo to estimate drug response, in pediatric and adult subjects. CNS tumors display remarkable heterogeneity and unfortunately th…
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC
-
Can paxlovid beat long COVID? major trial reveals results
Disease control CompletedThis is an appendix of master protocol (NCT05595369) designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This sub-study i…
Phase 2 • Sponsor: Kanecia Obie Zimmerman • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Can an antiviral cure long COVID? new trial tests paxlovid
Disease control CompletedThis study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, mul…
Phase 2 • Sponsor: Kanecia Obie Zimmerman • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Personalized drug attack on salivary gland tumors shows promise
Disease control OngoingThis is a single-center, open-label, phase 2 study to evaluate the efficacy and safety of target therapy for patients with relapsed/metastastic salivary gland carcinoma based on molecular typing.
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Experimental immune therapy takes on tough lymphomas
Disease control Recruiting nowThis is a Phase 1/1b, open-label, dose-escalation study to evaluate the safety and the efficacy of anti-CD19 chimeric antigen receptor (CAR) (TBI-2001) for relapsed or refractory CD19+ B-cell lymphoma Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL).
Phase 1 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Moderna tests mRNA shots to stop lyme disease
Vaccine CompletedThe purpose of this study is to evaluate the safety and immunogenicity in parallel of heptavalent mRNA-1975 and monovalent mRNA-1982 against Lyme disease in healthy adult participants.
Phase 1/2 • Sponsor: ModernaTX, Inc. • Aim: Vaccine
Last updated Aug 01, 2026 00:00 UTC
-
Vaccine combo aims to supercharge immune attack on HPV-Positive throat cancer
Disease control Recruiting nowThis phase II trial tests how well pB1-11 and human papillomavirus tumor antigen (TA-HPV) vaccines in combination with pembrolizumab work in treating patients with oropharyngeal cancer that has come back (recurrent) or that has spread from where it first started (primary site) to…
Phase 2 • Sponsor: Michael K. Gibson • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New hope for rare blood disorder: experimental pill reduces need for transfusions
Disease control CompletedBackground: Diamond-Blackfan anemia (DBA) is an inherited disease that affects the bone marrow. People with DBA have chronic anemia that can be severe. Many must have frequent transfusions of red blood cells. Current treatments for DBA all have risks of serious side effects. Bet…
Phase 1/2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC